Abstract
Objective: Tacrolimus is characterized by a restricted therapeutic index, a high inter- and intra-individual pharmacokinetic variability and a series of severe adverse effects. It is a substrate of cytochrome p-450 (CYP) 3A enzyme and of the drug transporter ABCB1.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
